173 related articles for article (PubMed ID: 15390053)
1. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine in restless legs syndrome.
Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
[TBL] [Abstract][Full Text] [Related]
3. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
4. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
[TBL] [Abstract][Full Text] [Related]
5. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
6. Oral vitamin B12 supplementation reduces plasma total homocysteine concentration in women in India.
Yajnik CS; Lubree HG; Thuse NV; Ramdas LV; Deshpande SS; Deshpande VU; Deshpande JA; Uradey BS; Ganpule AA; Naik SS; Joshi NP; Farrant H; Refsum H
Asia Pac J Clin Nutr; 2007; 16(1):103-9. PubMed ID: 17215186
[TBL] [Abstract][Full Text] [Related]
7. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
9. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels].
Lökk J
Lakartidningen; 2003 Aug; 100(35):2674-7. PubMed ID: 14531126
[TBL] [Abstract][Full Text] [Related]
11. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
Müller T; Renger K; Kuhn W
Arch Neurol; 2004 May; 61(5):657-60. PubMed ID: 15148140
[TBL] [Abstract][Full Text] [Related]
12. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
[TBL] [Abstract][Full Text] [Related]
14. Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients.
Belcastro V; Pierguidi L; Castrioto A; Menichetti C; Gorgone G; Ientile R; Pisani F; Rossi A; Calabresi P; Tambasco N
Eur J Neurol; 2010 May; 17(5):661-5. PubMed ID: 20050890
[TBL] [Abstract][Full Text] [Related]
15. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
18. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
19. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Di Rocco A; Werner P
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14981202
[No Abstract] [Full Text] [Related]
20. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Schroecksnadel K; Leblhuber F; Fuchs D
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14994447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
